share_log

大摩：予中国中药(00570)“增持”评级 目标价下调至4.9港元

DBS has rated China Traditional Chinese Medicine (00570) as a "shareholding" and lowered the target price to HKD 4.9.

Zhitong Finance ·  Jul 16 10:29

Daiwa Securities has lowered its profit forecast for China Traditional Chinese Medicine (00570) for the years 2024 to 2030 by 10% to 14%.

According to the Zhìtōng Finance app, Daiwa Securities released a research report stating that following the group purchasing price reduction in the first half of the year, considering the recent monthly trend, it will lower the profit forecast for China Traditional Chinese Medicine (00570) for the years 2024 to 2030 by 10% to 14%. The reason is that the sales and gross margin forecast for formula granules have been downgraded, and the target price has been lowered from HKD 5.4 to HKD 4.9, with a rating of "shareholding."

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment